Study design
This is a multicenter randomized controlled trial with two parallel arms. Recruiting patients will be carried out in Hubei Hospital of Traditional Chinese Medicine and Huangshi Hospital of Traditional Chinese Medicine. Data management and statistics will be conducted in the Department of Yue yang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine. Due to the limitations of intervention methods, only the outcome assessors and statisticians are blinded. It is planned to recruit 186 patients and randomly assign them to the conventional treatment group and the conventional treatment plus Dao Yin group at a 1: 1 ratio. Dao Yin intervention is conducted once a day lasting from admission to cure discharge. The assessor, who was masked to the group assignment, will perform evaluation and analysis of outcome at five points (before treatment, 3rd, 6th, 9th day during hospitalization and the discharge day). All patients are provided with informed consent at the time of recruitment, and the trial protocol was approved by the Ethics Committee of Yue yang Hospital of Integrated Traditional Chinese and Western Medicine (item number:2020-002). The study was registered with the China Clinical Trial Registry (ChiCTR2000029978). The trial flow chart and research design are shown in Figure 1 and Figure 2 respectively.
Participants recruitment
The trial will recruit clinical patients with mild and general symptom. The participants will be diagnosed by the criteria of the "Novel Coronavirus–infected Pneumonia (2019-nCoV) Diagnosis and Treatment Scheme (Trial Fifth Version)" issued by the National Health Commission of China on February 4, 202017. Participants are recruited from inpatients of the Department of Infectious Diseases of the two hospital in Hubei Province. All participants were between 18 and 60 years of age, with no difference in median age between the two groups.
Inclusion criteria
(1) The age of patients is between 18 and 60, and is not limited to male or female; (2) Patients diagnosed with mild pneumonia (slight clinical symptoms, no pneumonia manifestations on imaging), general pneumonia patients (with fever, respiratory tract symptoms, etc., imaging showed pneumonia but no multiple organ damage)17 (3) Hospitalized patients; (4) Volunteer to join the trial and sign the "informed consent”. (5) Promise not to perform other exercise activities.
Exclusion criteria
One of the following conditions cannot be included in this test. (1) patients with severe diseases such as cardiovascular, cerebrovascular, hematopoietic, digestive system or mental illness; (2 )pregnant and lactating women; (3) respiratory frequency> 30 times /min, showing respiratory failure; (4) complicated with other organ failure requires treatment by respiratory intensive care unit (ICU); (5) those who do not want to join the trial.
Drop out and suspension criteria
During the intervention period, patients have the right to withdraw for any reason in accordance with the Patient Management and Protection Regulations. One of the following conditions is considered the withdrawal criteria: (1) the patient did not implement the treatment plan as planned; (2) participated in other exercise programs during the trial; (3) case data are incomplete and affect the judgement of curative effect; (4) unbearable adverse events; (5) patients voluntarily withdrew on their own. It is worth noting that the trial will be immediately terminated with poor clinical efficacy or severe adverse events such as respiratory failure, severe acid-base balance disorders, sepsis and even shock.
Randomization
Clinical researchers will get a random sequence number which is automatically generated by a random number generator (SPSS21.0, SPSS Inc., Chicago, Illinois, USA), and sequentially number them in an opaque envelope. Researchers will open random allocation envelopes and assign participants accordingly. Eligible patients will be randomly divided into a conventional treatment group and a conventional treatment plus exercise training group, with 93 patients in each group.
Blinding
Participants and Dao Yin trainers are unable to be blind about group assignments due to the specific intervention, but the trainers will not know the assessment of outcomes. To reduce the risk of bias, evaluators, data managers, and statisticians were unaware of group assignments in the outcome evaluation process and data analysis.
Interventions
Both groups of participants will receive routine treatment. Based on this, the experimental group will perform Dao Yin once a day until the discharge day. The daily routine treatment plan must be recorded in the electronic medical record by the doctor's system. In order to avoid cross-infection and ensure the identity of the training content, the training method will be presented to the subjects in text and video, including exercise action essentials, time, intensity, and precautions. It should be emphasized that during the test, other exercise rehabilitation methods, including aerobic exercise, stretching exercise, yoga and other sports therapy will be prohibited. If the subject receives any other exercise regimen, the changes should be recorded on the Clinical Report Form (CRF) each time.
Conventional treatment group
For patients with mild and common pneumonia, doctors strictly follow the general treatment plan "Novel Coronavirus-infected Pneumonia Diagnosis and Treatment Scheme (Trial Fifth Version)" for symptomatic supportive treatment. It mainly includes (1) rest in bed, strengthen supportive treatment to ensure sufficient heat; pay attention to water and electrolyte balance to maintain internal environment stability; closely monitor vital signs, oxygen saturation, etc. ; (2) monitor blood routine, urine routine, liver based on the condition function, renal function, myocardial enzymes, coagulation function, chest imaging, etc. ;(3) timely effective oxygen therapy measures, including nasal catheter, mask oxygen and trans nasal high-flow oxygen therapy. (4) antiviral therapy, although no effective antiviral therapy has been confirmed. α-interferon atomized inhalation is suggested to use (5 million U each time for adults, add 2ml of sterilized water for injection, 2 times a day) (5) antibiotic treatment will be given if a bacterial infection is confirmed diagnosis. (6) accurate Chinese medicine treatment.
Conventional treatment plus Dao Yin group
The selection of the movements is based on the methodology of the Delphi Expert Questionnaire, which focused on the syndrome differentiation of traditional Chinese medicine on 2019-nCoV and the benefits of Dao Yin on physical and mental health. Finally, seven chapters of exercise training was formed, in which participants may perform systematic self-learning of exercises for half of the day. Patients will be given written materials and video materials about Dao Yin movements including action details. Researchers will start a remote video conference to monitor and correct the exercises throughout the whole trail process. When officially begin, patients will perform Dao Yin every day at 9 am, which mainly includes 2 minutes of warm-up exercise, 8 minutes of traditional exercise combined with breathing and stretching, and 2 minutes of cool down. Exercise training will be performed until patients discharged. The 7 steps detailed movement is shown in Figure 3. The study showed that certain exercise intensity can reach patient benefit goals18. Exercise intensity is adjusted gradually according to the patient's cardiopulmonary exercise function, from very low intensity (Heart Rate (HR)during exercise <57% or HR rise <30% Heart Rate rise (HRr) or Rating of Perceived Exertion (RPE)<9/20) → low intensity (HR during exercise 57-63% HRmax Or HRr 30-39% or RPE: 9-11/20) → moderate intensity (HR during exercise 64-76% HRmax or HRr 40-59% or RPE: 12-14/20).
Outcome measurements
All outcome will be managed by researchers masked to the group assignment, which include five points (before treatment, 3rd, 6th, 9th day during hospitalization and the discharge day) Outcomes included the patient's general vital signs, length of hospital stays, evaluation of dyspnea degree, mental health and immune cells.
Primary outcome measurement
Length of Hospital Stay (LHS)
The key to treating pneumonia is to access if it can shorten the hospitalization time and reach the discharge standard. So, we treat length of hospital stays as the primary outcome.
Secondary outcome measurement
1. Vital signs19
Blood pressure, heart rate, respiration, and blood oxygen saturation will be monitored three times a day by the nurse and then an average data will be obtained.
2. Mental health
The Motivation Assessment Scale (MAS)20 and Self Rating Depression Scale (SDS) 21will be used to assess the psychological condition of patients during illness. MAS comprises 16 questions that are rated on a seven-point Likert scale ranging from 0 (never) to 6 (always). Items load onto one of four categories of reinforcement: sensory, escape, attention and tangible. SDS is based on factor analytic studies of depression symptoms, which involve psychological and physical symptoms and are scored by users on a 4-point scale based on their use over the past week, ranging from 1 (no time or very little time) to 4 (most or all time).
3. Respiratory symptoms questionnaire
By quantifying dyspnea, the doctor can assess its severity and its impact on a person’s functional health status. Patients with dyspnea a will be evaluated through some functional questionnaires. Perceived breathlessness on daily activities was measured by means of the Medical Research Council (MRC) breathlessness/dyspnea scale 22and Modified Borg scale (MBS)23 that had the potential to provide quick, easy, and rapid information about a patient’s subjective state of dyspnea. The original MRC dyspnea scale contains five grades (from 1 to 5) of dyspnea description that are more easily self-administered by the participants. A commonly used format of MBS is a 10-point scale with a non-linear scaling scheme using descriptive terms to anchor responses.
4. Main elements of the immune system
Under the effect of exercise stress, T lymphocytes will be redistributed in large quantities in lymphoid and non-lymphoid organs. These stress-induced immune profiles will increase immune surveillance and vigilances24. T-cell and Natural Killer cell will be detected in peripheral blood with the Flow cytometry25method to gain more insights into the underlying connection between exercise and immune respond.
Safety evaluation
The doctors should focus on the vital signs of patients with 2019-nCoV strictly to decrease the incidence of adverse events, which is refer to the unexpected responses that occur during or after treatment. Record and analyze them whether the adverse events are related to the treatment. If a serious adverse reaction occurs, the researchers should immediately take appropriate medical measures according to the situation. Liver function and renal function tests and lung CT imaging tests also need to be monitored.
Data collecting and monitoring
During the recruitment phase, screeners will collect demographics of the participants. The data assessor will record the baseline characteristics of the patient, the length of hospital stays, general vital signs, the questionnaire to evaluate respiratory function and psychological status, and the levels of immune cells through a CRF. Next, two third-party personnel who have received strict data management training will receive data in the form of an excel database, and then they will enter the real-time data into the China Clinical Trial Registration Center. This electronic data management system will be used in the Ministry of Science and Technology of Yue yang Hospital of Integrated Traditional Chinese and Western Medicine to collect and monitor test data in real time.
Statistical analyses
Statisticians will use SPSS Windows version 21.0 software to perform the data analysis within group and between groups. Data will be expressed as mean ± standard deviation. The data between groups will be compared by Student’s t test when the continuous variables can meet a normal distribution or T distribution. Otherwise, Mann–Whitney test or Wilcoxon test will be used. For categorical data, the Fisher’s exact or the Chi-square test will be adopted. We will conduct an intention-to-treat analysis if participants are lost to follow-up and perform a simple correlation analysis or simple regression analysis to determine the potential correlation between the outcome measurements. Adverse events in each group will be documented as percentage (%) for safety assessments using the chi-square test or Fisher’s exact test. All statistical analyses will be conducted in a two-sided manner, with a significance level of 5%.
Sample size calculation
The trial takes the LHS as the primary efficacy outcome. With reference to the latest literature3, it is assumed that the average length of stay in the control group of this study is 10 days, the standard deviation is 3 days, and the average length of stay in the treatment group is 8.5 days, α = 0.05 , β = 0.10. Considering the 10% drooping rate, it was calculated that 93 subjects were needed in each group, and a total of 186 cases were required to be recruited.
Quality control
Professional trial methodology should be trained before the researchers participate in the trial which can ensure the consistency of methods. Quality control will be conducted during the processing of the trail under the management of the steering committee. Supervisors will review the quality control of the trials via remote video surveillance, frequency is once every 2 weeks and recorded. Anything modification in the study protocol happen will inform the steering committee and ethics committee.